 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...7677787980818283848586...100101» |
- || letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Evaluation of IM Letrozole ISM (clinicaltrials.gov) - Jan 22, 2019
P1, N=120, Recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
Trial completion date: Sep 2019 --> Jul 2020 | Trial primary completion date: Apr 2019 --> Jul 2020
- |||| Ibrance (palbociclib) / Pfizer
New P2 trial, Metastases: PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (clinicaltrials.gov) - Jan 18, 2019
P2, N=198, Not yet recruiting, Sponsor: MedSIR
- ||| Ibrance (palbociclib) / Pfizer
Enrollment open: Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Jan 15, 2019
P2, N=76, Recruiting, Sponsor: NSABP Foundation Inc
Trial completion date: Sep 2019 --> Jul 2020 | Trial primary completion date: Apr 2019 --> Jul 2020 Not yet recruiting --> Recruiting
- ||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion date: NSABP B-42: Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - Jan 9, 2019
P3, N=3966, Active, not recruiting, Sponsor: NSABP Foundation Inc
Not yet recruiting --> Recruiting Trial completion date: Oct 2018 --> Dec 2019
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Jan 8, 2019
P3, N=3775, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2018 --> Dec 2019 Initiation date: Sep 2012 --> Nov 2016
- | Kisqali (ribociclib) / Novartis
Trial completion date, Metastases: NCI-2018-01284: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jan 8, 2019
P2, N=76, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Sep 2012 --> Nov 2016 Trial completion date: Aug 2023 --> Aug 2022
- | Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: PALINA: Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer (clinicaltrials.gov) - Jan 4, 2019
P2/3, N=35, Active, not recruiting, Sponsor: Georgetown University
Trial completion date: Aug 2023 --> Aug 2022 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Nov 2019
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Jan 3, 2019
P4, N=300, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Nov 2019 Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- ||| zotatifin (eFT226) / eFFECTOR Therap, Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Combination therapy: RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) - Jan 3, 2019
P2, N=62, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Not yet recruiting --> Recruiting
- | hydrocortisone / Generic mfg., flutamide / Generic mfg.
Phase classification, Combination therapy: Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Dec 28, 2018
P2, N=62, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Recruiting Phase classification: P1 --> P2
- letrozole / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin (clinicaltrials.gov) - Dec 27, 2018
P=N/A, N=9, Completed, Sponsor: University of Kansas
Phase classification: P1 --> P2 Recruiting --> Completed | N=12 --> 9 | Trial primary completion date: Jun 2015 --> Aug 2014
- || xentuzumab (BI-836845) / Boehringer Ingelheim
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - Dec 26, 2018
P1, N=148, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | N=12 --> 9 | Trial primary completion date: Jun 2015 --> Aug 2014 N=88 --> 148 | Trial completion date: Jul 2020 --> Nov 2021 | Trial primary completion date: Dec 2019 --> Apr 2020
- ||| Ibrance (palbociclib) / Pfizer
Enrollment open: To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (clinicaltrials.gov) - Dec 19, 2018
P2, N=144, Recruiting, Sponsor: International Breast Cancer Study Group
N=88 --> 148 | Trial completion date: Jul 2020 --> Nov 2021 | Trial primary completion date: Dec 2019 --> Apr 2020 Not yet recruiting --> Recruiting
- |||||||||| Orserdu (elacestrant) / Menarini
New P3 trial, Monotherapy, Metastases: EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov) - Dec 19, 2018
P3, N=466, Recruiting, Sponsor: Radius Pharmaceuticals, Inc.
- ||| Ibrance (palbociclib) / Pfizer
Trial completion, Combination therapy, Metastases: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Dec 13, 2018
P2, N=61, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer
New P1/2 trial: NCI-2018-01050: Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Dec 13, 2018
P1/2, N=54, Recruiting, Sponsor: M.D. Anderson Cancer Center
- || xentuzumab (BI-836845) / Boehringer Ingelheim
Trial primary completion date, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - Dec 12, 2018
P1, N=88, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Dec 2019
- | letrozole / Generic mfg.
Enrollment open: Intrauterine Insemination With Letrozole Versus in Natural Cycle (clinicaltrials.gov) - Dec 11, 2018
P=N/A, N=100, Enrolling by invitation, Sponsor: Peking University Third Hospital
Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Enrolling by invitation
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P1/2 trial, Combination therapy, Metastases: PLEASURABLE: Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (clinicaltrials.gov) - Dec 11, 2018
P1/2, N=32, Not yet recruiting, Sponsor: Fudan University
- | letrozole / Generic mfg.
Clinical, P2 data, Journal: A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). (Pubmed Central) - Dec 8, 2018
While no definitive conclusions can be made due to early study closure, these early observations warrant further investigation. We desperately need an effective adjuvant therapy for women with early stage uLMS.
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Enrollment closed, Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Dec 5, 2018
P1, N=256, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
We desperately need an effective adjuvant therapy for women with early stage uLMS. Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2019 --> Nov 2019
- || Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion, Metastases: Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone (clinicaltrials.gov) - Dec 5, 2018
P2, N=44, Completed, Sponsor: Translational Research in Oncology
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2019 --> Nov 2019 Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: Palbociclib and FES PET (clinicaltrials.gov) - Dec 5, 2018
P2, N=15, Active, not recruiting, Sponsor: University Medical Center Groningen
Active, not recruiting --> Completed Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- | Trial completion: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy (clinicaltrials.gov) - Dec 4, 2018
P2, N=297, Completed, Sponsor: Janssen Research & Development, LLC
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Active, not recruiting --> Completed
- |||| Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] (clinicaltrials.gov) - Dec 4, 2018
P3, N=339, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: Mar 2019 --> Nov 2019
- | imatinib / Generic mfg., letrozole / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer (clinicaltrials.gov) - Nov 30, 2018
P2, N=59, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2019 --> Nov 2019 Active, not recruiting --> Completed | N=45 --> 59 | Trial completion date: Oct 2019 --> Nov 2018 | Trial primary completion date: Oct 2019 --> Nov 2018
- | letrozole / Generic mfg.
Enrollment open: Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer (clinicaltrials.gov) - Nov 29, 2018
P1, N=300, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed | N=45 --> 59 | Trial completion date: Oct 2019 --> Nov 2018 | Trial primary completion date: Oct 2019 --> Nov 2018 Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Clinical, P3 data, Journal: Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. (Pubmed Central) - Nov 28, 2018
P3
In postmenopausal women with hormone receptor-positive breast cancer, extended use of intermittent letrozole did not improve disease-free survival compared with continuous use of letrozole. An alternative schedule of extended adjuvant endocrine therapy with letrozole, including intermittent administration, might be feasible and the results of the SOLE trial support the safety of temporary treatment breaks in selected patients who might require them.
- | Trial completion date, Trial primary completion date: Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients (clinicaltrials.gov) - Nov 23, 2018
P3, N=107, Recruiting, Sponsor: Dharmais National Cancer Center Hospital
An alternative schedule of extended adjuvant endocrine therapy with letrozole, including intermittent administration, might be feasible and the results of the SOLE trial support the safety of temporary treatment breaks in selected patients who might require them. Trial completion date: Mar 2018 --> Jan 2019 | Trial primary completion date: Mar 2018 --> Dec 2018
- | Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Nov 21, 2018
P1, N=88, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2018 --> Jan 2019 | Trial primary completion date: Mar 2018 --> Dec 2018 Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2020
- | Soltamox (tamoxifen citrate) / Jazz
Enrollment change, Trial withdrawal: Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer (clinicaltrials.gov) - Nov 21, 2018
P4, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Research Center
Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2020 N=600 --> 0 | Not yet recruiting --> Withdrawn
- | letrozole / Generic mfg.
New P1 trial: Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer (clinicaltrials.gov) - Nov 20, 2018
P1, N=300, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: MA.17R: Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy (clinicaltrials.gov) - Nov 19, 2018
P3, N=1918, Completed, Sponsor: Canadian Cancer Trials Group
N=600 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Nov 19, 2018
P2, N=40, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Active, not recruiting --> Completed Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion date, Trial primary completion date: TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov) - Nov 13, 2018
P3, N=144, Recruiting, Sponsor: University of California, San Francisco
Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019 Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019
- | Kisqali (ribociclib) / Novartis
Enrollment closed, Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Nov 8, 2018
P3, N=3258, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019 Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012
- | Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Nov 7, 2018
P1/2, N=40, Recruiting, Sponsor: Academic Thoracic Oncology Medical Investigators Consortium
Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012 Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019
- | Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Oct 31, 2018
P1, N=270, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019 Trial completion date: May 2019 --> Dec 2019
- | Clinical, Review, Journal, Combination therapy, Monotherapy: Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review. (Pubmed Central) - Oct 27, 2018
Trial completion date: May 2019 --> Dec 2019 ET + CDK4/6 or mTOR inhibitors are likely safe and effective in older patients with HR+, HER2- advanced breast cancer.
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects (clinicaltrials.gov) - Oct 26, 2018
P1, N=60, Recruiting, Sponsor: Andrew Brenner
ET + CDK4/6 or mTOR inhibitors are likely safe and effective in older patients with HR+, HER2- advanced breast cancer. Trial completion date: Sep 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | Trial completion date, Trial primary completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - Oct 24, 2018
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Trial completion date: Mar 2021 --> Sep 2021 | Trial primary completion date: Jun 2019 --> Dec 2019
- | letrozole / Generic mfg., megestrol / Generic mfg.
Trial completion date, Trial primary completion date: PIONEER: A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer (clinicaltrials.gov) - Oct 24, 2018
P2, N=189, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Trial completion date: Mar 2021 --> Sep 2021 | Trial primary completion date: Jun 2019 --> Dec 2019 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- ||| Ibrance (palbociclib) / Pfizer, Kadcyla (ado-trastuzumab emtansine) / Roche
Enrollment open, Metastases: Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (clinicaltrials.gov) - Oct 19, 2018
P1/2, N=62, Recruiting, Sponsor: University of Kansas Medical Center
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- |||| Ibrance (palbociclib) / Pfizer, Kadcyla (ado-trastuzumab emtansine) / Roche
New P1/2 trial, Metastases: Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (clinicaltrials.gov) - Oct 17, 2018
P1/2, N=62, Not yet recruiting, Sponsor: University of Kansas Medical Center
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: PLUM: Pilot of Letrozole for Uterine Myomas (clinicaltrials.gov) - Oct 16, 2018
P4, N=12, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Trial completion date: Aug 2017 --> Dec 2017 | Trial primary completion date: Aug 2017 --> Dec 2017
- | letrozole / Generic mfg.
Trial completion date, Trial termination, Trial primary completion date, Surgery: Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Oct 15, 2018
P1, N=213, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Aug 2017 --> Dec 2017 | Trial primary completion date: Aug 2017 --> Dec 2017 Trial completion date: Sep 2019 --> Sep 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2019 --> Sep 2018; funding unavailable
- || PF-06804103 / Pfizer
Trial completion date, Trial primary completion date: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) - Oct 15, 2018
P1, N=95, Recruiting, Sponsor: Pfizer
Trial completion date: Sep 2019 --> Sep 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2019 --> Sep 2018; funding unavailable Trial completion date: Feb 2021 --> Jun 2021 | Trial primary completion date: Feb 2021 --> Jun 2021
- everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Oct 9, 2018
P2, N=4, Active, not recruiting, Sponsor: Emory University
Trial completion date: Feb 2021 --> Jun 2021 | Trial primary completion date: Feb 2021 --> Jun 2021 Trial completion date: Sep 2019 --> Oct 2020 | Trial primary completion date: Sep 2018 --> Oct 2019
- || Enrollment closed, PARP Biomarker: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (clinicaltrials.gov) - Oct 9, 2018
P2, N=200, Active, not recruiting, Sponsor: Haukeland University Hospital
Trial completion date: Sep 2019 --> Oct 2020 | Trial primary completion date: Sep 2018 --> Oct 2019 Recruiting --> Active, not recruiting
- | letrozole / Generic mfg.
Enrollment open: Letrozole Pretreatment With Misoprostol fInduction of Abortion In First-Trimester Missed Miscarriage (clinicaltrials.gov) - Oct 9, 2018
P2, N=80, Recruiting, Sponsor: Ain Shams Maternity Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting